FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Ornskov Flemming
2. Issuer Name and Ticker or Trading Symbol

WATERS CORP /DE/ [ WAT ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

34 MAPLE STREET
3. Date of Earliest Transaction (MM/DD/YYYY)

9/30/2019
(Street)

MILFORD, MA 01757
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                 1755  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units   (1) 9/30/2019    A     127.42      9/30/2019   (2) Common Stock  127.42  $0  127.42  D   

Explanation of Responses:
(1)  COMMON STOCK UNITS ARE CONVERTIBLE INTO COMMON STOCK SHARES ON A ONE TO ONE RATIO.
(2)  UPON RESIGNATION AS DIRECTOR.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Ornskov Flemming
34 MAPLE STREET
MILFORD, MA 01757
X



Signatures
/s/ Dr. Flemming Ornskov 10/1/2019
**Signature of Reporting Person Date


Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Waters Charts.
Waters (NYSE:WAT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Waters Charts.

Waters Corp /de/ News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns
Monday 22 April 2024 (2 weeks ago) • PR Newswire (US)
Waters Corporation Schedules First Quarter 2024 Earnings Conference Call
Friday 12 April 2024 (3 weeks ago) • PR Newswire (US)
Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors
Tuesday 9 April 2024 (4 weeks ago) • PR Newswire (US)
Waters Streamlines and Expedites PFAS Testing with Innovative Oasis Dual-Phase Cartridges
Thursday 14 March 2024 (2 months ago) • PR Newswire (US)
Waters Advances Battery Electrode Design and Performance Analysis with New Rheo-IS Accessory
Wednesday 13 March 2024 (2 months ago) • PR Newswire (US)
Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Waters Announces Seamless HPLC/UPLC Data Bridge for Light Scattering, Integrating Essential Instruments for Large Molecule Characterization
Tuesday 27 February 2024 (2 months ago) • PR Newswire (US)
Waters Corporation to Present at the TD Cowen 44th Annual Health Care Conference
Friday 23 February 2024 (2 months ago) • PR Newswire (US)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Saturday 10 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Saturday 10 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Saturday 10 February 2024 (3 months ago) • Edgar (US Regulatory)